Please provide your email address to receive an email when new articles are posted on . VT-1953, a first-in-class topical immunomodulator, improved malodor associated with malignant fungating wounds ...

VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P = 0.002).

Selby, T. (2009) Managing exudate in malignant fungating wounds and solving problems for patients. 105: 18; early online publication. Excessive exudate is a common characteristic of malignant ...

VT-1953 treatment significantly reduced malignant fungating wound-associated malodor (primary endpoint) (P<0.001). Patients also reported significant improvements in lesion pain (P<0.001) and Quality ...

CAMBRIDGE, MA, UNITED STATES, January 22, 2025 /EINPresswire.com/ -- • VT-1953 treatment reduces malignant fungating wound-associated malodor over a 14 day period ...

Completed a streamlined Nasdaq listing, with a 100% common stock capital structure Delivered encouraging interim Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line ...

Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion Modeled peak annual U.S. sales approaching USD 600 million for VT-1953 Independent valuation ...

Pyoderma gangrenosum is a difficult-to-treat wound disease that may soon have promising new therapies. Chronic wounds are an immense burden for patients. If left untreated, chronic wounds can be ...

CAMBRIDGE, MA, UNITED STATES, January 22, 2025 /EINPresswire / -- .VT-1953 treatment reduces malignant fungating wound-associated malodor over a 14 day period as measured using the TELER scale ...